These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 29548051)
21. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. Paul Y; Mondal B; Patil V; Somasundaram K Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842 [TBL] [Abstract][Full Text] [Related]
22. Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. Sturm D; Pfister SM; Jones DTW J Clin Oncol; 2017 Jul; 35(21):2370-2377. PubMed ID: 28640698 [TBL] [Abstract][Full Text] [Related]
23. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. Macaulay RJ Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765 [TBL] [Abstract][Full Text] [Related]
24. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047 [TBL] [Abstract][Full Text] [Related]
25. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI. Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279 [TBL] [Abstract][Full Text] [Related]
26. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis. Appin CL; Brat DJ Adv Anat Pathol; 2015 Jan; 22(1):50-8. PubMed ID: 25461780 [TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance metabolic imaging of glioma. Metellus P; Figarella-Branger D Sci Transl Med; 2012 Jan; 4(116):116ps1. PubMed ID: 22238331 [TBL] [Abstract][Full Text] [Related]
28. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430 [TBL] [Abstract][Full Text] [Related]
29. A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. Roth P; Hottinger AF; Hundsberger T; Läubli H; Schucht P; Reinert M; Mamot C; Roelcke U; Pesce G; Hofer S; Weller M Swiss Med Wkly; 2020 Jun; 150():w20256. PubMed ID: 32557428 [TBL] [Abstract][Full Text] [Related]
30. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362 [TBL] [Abstract][Full Text] [Related]
31. Low-Grade Gliomas: A New Mutation, New Targeted Therapy, and Many Questions. Schiff D Neurology; 2024 Aug; 103(3):e209688. PubMed ID: 39008801 [TBL] [Abstract][Full Text] [Related]
32. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. Natsumeda M; Igarashi H; Nomura T; Ogura R; Tsukamoto Y; Kobayashi T; Aoki H; Okamoto K; Kakita A; Takahashi H; Nakada T; Fujii Y Acta Neuropathol Commun; 2014 Nov; 2():158. PubMed ID: 25376594 [TBL] [Abstract][Full Text] [Related]
33. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345 [TBL] [Abstract][Full Text] [Related]
34. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382 [TBL] [Abstract][Full Text] [Related]
35. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline. Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880 [TBL] [Abstract][Full Text] [Related]
36. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154 [TBL] [Abstract][Full Text] [Related]
37. IDH1 status is significantly different between high-grade thalamic and superficial gliomas. Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450 [TBL] [Abstract][Full Text] [Related]
38. Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas. Picca A; Di Stefano AL; Sanson M Curr Opin Neurol; 2018 Dec; 31(6):727-732. PubMed ID: 30239358 [TBL] [Abstract][Full Text] [Related]
39. Association between Deng L; Xiong P; Luo Y; Bu X; Qian S; Zhong W; Lv S Oncol Lett; 2018 Oct; 16(4):5405-5409. PubMed ID: 30250611 [TBL] [Abstract][Full Text] [Related]
40. Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal? Tom MC; Cahill DP; Buckner JC; Dietrich J; Parsons MW; Yu JS Am Soc Clin Oncol Educ Book; 2019 Jan; 39():133-145. PubMed ID: 31099638 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]